1 / 39

CORPORATE PLAN 2015/16 – 2017/18

This presentation provides an overview of OBP's strategic goals, organizational structure, policy and legal framework, governance, and financial overview. It highlights OBP's mission to improve animal and human health through the development of pharmaceutical health products.

gbowen
Download Presentation

CORPORATE PLAN 2015/16 – 2017/18

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Presentation to the Portfolio Committee CORPORATE PLAN 2015/16 – 2017/18 Onderstepoort Biological Products March 2015 i

  2. Content • Introduction to OBP delegation • Strategic Overview • Organisational Overview • Policy and Legal Framework • Delivery on Mandate • Governance • Annual Performance Plan & Strategic Plan • Financial Overview and Approved Budget 2014/15 • Conclusion Onderstepoort Biological Products March 2015 Page 1

  3. Delegation Board Members OBP Executives Dr S Cornelius : Chief Executive Officer Mr M. Gololo : Chief Financial Officer Ms Z. Mobeng : Executive Manager: Legal, Compliance and Company Secretary Dr J Modumo : Business Development Officer Dr JH Adams Onderstepoort Biological Products March 2015 Page 2

  4. Strategic Overview Vision • OBP’s vision is to be a global pharmaceutical and biotechnology manufacturer of animal health products underpinned by a skilled, innovative, and passionate team, as well as new technologies. Mission • Its mission is to translate science into pharmaceutical (biological) health products and technologies resulting in improved animal and human health, and food security. Supporting Values • OBP conducts its business and operations guided by the following values: • Integrity and professional ethics • Customer satisfaction through securing animal health • High standards of quality and excellence • Promoting creativity, innovation, and teamwork Onderstepoort Biological Products March 2015 Page 3

  5. Organisational Overview • Schedule 3B public entity • Reports to the Minister of Agriculture, Forestry and Fisheries • Minister & Cabinet appoint Board • Subject to the PFMA & other Treasury regulations • 194 employees – Scientific, Administrative, Agricultural • The organisation has two policy mandate areas, namely: • Public good - To ensure that the government’s responsibility in terms of food security and safety is met through the development, security and availability of critical vaccine reserves; and • Private good - Referring to the ability of the organisation to manufacture, distribute and sell vaccines for financial gain • Product portfolio comprises more than 50 veterinary vaccines against viral, bacterial, and protozoal diseases of cattle, sheep, goats, poultry and horses. Onderstepoort Biological Products March 2015 Page 4

  6. Policy and Legal Mandate Constitutional Mandate • Bill of Rights to the Constitution sets out in Section 27 (b) that “everyone has the right to have access to sufficient food and water”. Legal Mandate • Onderstepoort Biological Products Incorporation Act 19 of 1999 read in conjunction with Onderstepoort Biological Products Memorandum of Incorporation (MOI). • Schedule 3B public entity in terms of the Public Finance Management Act, Act 1 of 1999 - accounts to the Minister of Agriculture, Forestry and Fisheries (Executive Authority). Policy Mandate • Policy mandate of OBP is derived from government’s strategic and policy priorities, Outcome 7, “Vibrant, equitable and sustainable rural communities with food security for all.” Onderstepoort Biological Products March 2015 Page 5

  7. Constitutional mandate The The role of OBP is supporting livestock production, which contributes to this inalienable right. 2.2 Legislative mandate OBP is governed by the Onderstepoort Biological Products Act 19 of 1999, which should be read together with Onderstepoort Biological Products Memorandum of Incorporation (MOI). Other legislation and strategies applicable to OBP include: Policy and Legal Mandate (cont.) • OBP delivers on the government’s responsibility to ensure food safety and security through maintaining animal health. Other legislation and strategies pertaining to its core function are: • Intellectual Property Rights from Publicly Financed Research and Development Act, 2008 • Employment Equity Act 55 of 1998 • Basic Conditions of Employment Act 75 of 1997 • Skills Development Act 97 of 1988 • Public Finance Management Act 1 of 1999 (as amended by Act 29 of 1999) • Relevant Treasury regulations (including the new revision) and guidelines • Animal Protection Act, 1962 (Act No. 71 of 1962) • Veterinary and Para-Veterinary Profession Act, 1982, (Act No. 19 of 1982) • Animal Disease Act, 1984 (Act No. 35 of 1984) • Non-Proliferation of Weapons of Mass Destruction Act, 1993 (Act No. 87 of 1993) • Genetically Modified Organisms Act, 1997 (Act No 15 of 1997) • Animal Health Act, 2002 (Act No 7 of 2002) • Intellectual Property Laws Amendment Act 2013 • Occupational Health and Safety Act, 1993 (Act No 85 of 1993) • DAFF Strategic Plan – 2014 - 2016 • Department of Science and Technology Bio-Economic Strategy • Consumer Protection Act, (Act No. 68 of 2008, as amended) Onderstepoort Biological Products March 2015 Page 6

  8. Delivery on mandate • Mandate is reflected in Corporate Plan (CP) & Annual Performance Plan (APP) & is part of protocol agreement with DAFF • CP is a tool to organise, manage, prioritise & deliver on the broad OBP mandate • CP & APP are approved by the Board & DAFF & submitted to Parliament & National Treasury • Targets are monitored through quarterly progress report which is reviewed by DAFF and Treasury • Performance information is audited by the Auditor-General Onderstepoort Biological Products March 2015 Page 7

  9. Alignment to government programmes Onderstepoort Biological Products March 2015 Page 8

  10. Alignment to Government Programmes • National Development Plan: • Economy and employment, economic infrastructure, inclusive rural economy, positioning SA in the world. • PICC SIP11: • Agri-logistics and infrastructure • MTSF: • Outcome 7: Vibrant, equitable, sustainable rural communities, contributing towards food security for all. • New growth path: • Job driver 2 – Improving job creation in economic sectors: Agricultural value chain & Manufacturing. • Job driver 3 – Seizing the potential of new economies: Knowledge economy • DAFF’s strategic plan: • Strategic Goal 1: Increased profitable production of food, fibre and timber products by all categories of producers (subsistence, smallholder and commercial • Strategic Goal 5: Increase contribution of the sector to economic growth and development Onderstepoort Biological Products March 2015 Page 9

  11. Alignment to Government Programmes Onderstepoort Biological Products March 2015 Page 10

  12. Alignment to Government Programmes Onderstepoort Biological Products March 2015 Page 11

  13. Alignment to Government Programmes Onderstepoort Biological Products March 2015 Page 12

  14. GOVERNANCE Onderstepoort Biological Products March 2015 Page 13

  15. Board of Directors • Board appointed on 15 May 2014 and Chairperson of Board on 1 August 2011 and term further extended for a period of 3 years. • 3 Sub-committees : • Audit, Risk and IT Committee • Remco, HR and Ethics Committee • Research , Development & Operations Committee (RDO Committee) • Board and Committees - 4 scheduled meetings per annum Onderstepoort Biological Products March 2015 Page 14

  16. High level structure • Based on the mandate and strategies, the operations of the OBP consist of a manufacturing plant, research and development, and support functions, which are executed through six executives, namely • Chief Operations Officer, Chief Financial Officer, Chief Scientific Officer, Business Development Officer, Human Resources Executive, and Quality Executive as well as the Strategic Projects and Planning unit. Onderstepoort Biological Products March 2015 Page 15

  17. Chief .Executive Officer • Dr Steven Cornelius Driving high-performance …. Executive Team • Extensively and appropriately experienced. Onderstepoort Biological Products March 2015 Page 16

  18. Corporate plan & annual performance plan Onderstepoort Biological Products March 2015 Page 17

  19. Strategic Objectives The OBP responds to national priorities in line with its mandate: 1: Build a global high-performing organisation equipped with modern technology and expertise to develop and manufacture competitive products to achieve financial sustainability. 2: Improve stakeholder relationship management and Communications. 3: Facilitate more aggressive national and international market access and implement an effective distribution strategy. 4: Continuously review research and development strategies in line with market trends. 5: Contribute to government priorities with respect to the provision of support to emerging farmers, food security, and economic growth. Onderstepoort Biological Products March 2015 Page 18

  20. Strategic Goal 1 and Targets Onderstepoort Biological Products March 2015 Page 19

  21. Strategic Goal 1 and Targets Onderstepoort Biological Products March 2015 Page 20

  22. Strategic Goal 1 and Targets Onderstepoort Biological Products March 2015 Page 21

  23. Strategic Goal 1 and Targets Onderstepoort Biological Products March 2015 Page 22

  24. Strategic Goal 1 and Targets Onderstepoort Biological Products March 2015 Page 23

  25. Strategic Goal 2 and Targets Onderstepoort Biological Products March 2015 Page 24

  26. Strategic Goal 3 and Targets Onderstepoort Biological Products March 2015 Page 25

  27. Strategic Goal 4 and Targets Onderstepoort Biological Products March 2015 Page 26

  28. Strategic Goal 5 and Targets Onderstepoort Biological Products March 2015 Page 27

  29. Financial overview and strategic objectives Onderstepoort Biological Products March 2015 Page 28

  30. Financial Overview and Approved Budget 2015/16 to 2017/18 Expenditure per programme Onderstepoort Biological Products March 2015 Page 29

  31. Capital Expenditure (estimated) Onderstepoort Biological Products March 2015 Page 30

  32. IncomeStatement Onderstepoort Biological Products March 2015

  33. BalanceStatement Onderstepoort Biological Products March 2015 Page 32

  34. Cash Flow Onderstepoort Biological Products March 2015 Page 33

  35. Conclusion • Investing profits in: • Development of improved and new vaccines. • Replacing critical equipment to maintain manufacturing capacity. • Emerging sector: • Support through provincial government • Rural vaccine distribution opportunities • Training and capacitation for new way of work: • Learnership and Internship programme • .Change Management • Upgrading of infrastructure and GMP project high priority • Improving customer relations • Concerted effort to recapture and increase markets Onderstepoort Biological Products March 2015 Page 34

  36. Supporting documents Onderstepoort Biological Products March 2015 Page 35

  37. OBP Product Portfolio Bacterial Vaccine Products Viral Vaccine Products • Actinomyces (Corynebacterium) pyogenes • Anthrax • Black Quarter • Botulism • Botulism/black quarter • Blue Udder • Brucella Rev 1 • Brucella S19 • Calf paratyphoid (live & inactivated) • Corynebacterium Ovis • E Coli • Enterotoxaemia (pulpy kidney) • Fowl Typhoid • Gangrene Complex • Haemophilus Coryza • Lamb Dysentry • Leukopast 3 (with IBR and PI) • Leukopast • Pasteurella Bovine • Pasteurella Ovine • Septicum • Swelled Head • Tetanus • Vibrio (Campylobacter) • Rift Valley Fever – live, inactivated, Clone 13 • African horse sickness • Bluetongue • B-Phemeral • Chlamysure • Lumpyskin • PI and IBR (in Leukopast 3) • Fowl Pox • ORF • Equine Influenza • Other Products • Frozen infective blood against (in conjunction with ARC-OVI) • Anaplasmosis • Heartwater • Redwater African / Babesiosis • Redwater Asiatic / Babesiosis Antiserum • Diagnostic Reagents (eg dourine, rose bengal) Onderstepoort Biological Products March 2015 Page 36

  38. Project Team estimates Onderstepoort Biological Products March 2015 Page 37

  39. Thank you Dr Steven Cornelius Chief Executive Officer Onderstepoort Biological Products March 2015

More Related